EGEric P. Grewal

Eric P. Grewal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric P. Grewal has a total of 126 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Letter to the EditorTumor-infiltrating lymphocyte therapy generated from melanoma brain metastasis: Proof-of-concept for CNS-derived cellular immunotherapy

    by Eric P Grewal, Samuel J Steuart, Baolin Liu, Hongyan Xie, Derek N Effiom, Aleigha R Lawless, Tatyana Sharova, Caroline Zielinski, Howard L Kaufman, Brian V Nahed, et al.

  • A Web‐Based Calculator for Hematopoietic Progenitor Cell Collections: App Development and Retrospective Assessment

    by Maxwell T. Roth, Jun Liu, Sanjana B. Shah, Claire Shao, Maria Y. Chen, Amelia K. Haj, Eric P. Grewal, Dennis Feeney, Kendra Munkacsy, Nelya Christiansen, et al.

    A major challenge in hematopoietic progenitor cell apheresis is determining the whole blood (WB) volume to process to achieve a CD34+ cell collection goal. We developed a web‐based calculator app that uses the Collection Efficiency 2 (CE2) model to estimate personalized WB processing volumes needed to reach a prescribed CD34+ cell collection goal. Retrospective evaluation of the app using collection data from two academic medical centers showed that actual processed WB volumes were frequently higher than the app's recommendations. The frequency of potential under‐collection events is predicted to be low had the app‐calculated volumes been utilized. Our findings suggest that using the app's recommendations may lower total WB processing volumes, reducing over‐collection and time spent on the apheresis machine, while maintaining a low under‐collection risk profile.

  • Open Access

    Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential

    by George Liu, Guillaume De Vlaminck, Osayamen Atekha, Eric P. Grewal, Rishab Ramapriyan, Gautam Agarwal

    Atherosclerosis is a chronic vascular disease that underlies the pathogenesis of both peripheral arterial disease and coronary artery disease, two of the leading causes of morbidity and mortality worldwide. Characterized by the accumulation of lipids, chronic inflammation, and fibrotic remodeling within vasculature, atherosclerosis involves a complex interplay of endothelial dysfunction, immune dysregulation, vascular smooth muscle cell proliferation, and maladaptive neovascularization. Increasing evidence now suggests that atherosclerosis has notable overlap with cancer biology, including sustained proliferative signaling, evasion of immune surveillance, angiogenesis, and resistance to cell death. These shared molecular features have prompted growing interest in the potential repurposing of oncologic treatments in the modulation of atherosclerotic disease. While preclinical data are promising, successful translation and integration of oncologic therapeutics will require overcoming critical barriers, including drug toxicity, long-term safety, regulatory constraints, and cost-effectiveness. Future work should focus on biomarker-guided patient selection, dose optimization, and targeted delivery systems to minimize off-target effects while enhancing efficacy.


  • Open Access

    A Review of Emerging Immunotherapeutic Strategies for IDH-Mutant Glioma

    by Masih Tazhibi, Eric P. Grewal, Rishab Ramapriyan, Leland G. K. Richardson, Gust Vandecandelaere, Adrian Kalaw, Parker Kotlarz, Samuel J. Steuart, Jing Sun, Matthew Gaffey, et al.

    IDH-mutant gliomas (IMGs) are a unique subset of diffuse gliomas that follow a relatively indolent course compared to IDH-wildtype glioblastoma (GBM) but inevitably progress, often to a higher histologic grade. Current standard therapies, including surgery, chemoradiation, and the recently approved mutant IDH inhibitor (mIDHi) vorasidenib, provide limited disease control and are not curative. Given the immunosuppressive tumor microenvironment (TME) driven by the mutant IDH enzyme and its associated oncometabolite 2-hydroxyglutarate (2-HG), novel immunotherapies offer a promising avenue for treatment. The goal of this paper is to review the main immunologic characteristics that distinguish IMG from GBM, including reduced T cell infiltration and function, fewer myeloid cells, and increased immune-dampening signaling. We also evaluate the preclinical and clinical evidence for immunotherapeutic approaches with the most potential to induce meaningful clinical activity, such as immune checkpoint inhibitors, CAR T cells, tumor vaccines, myeloid redirection, and oncolytic viruses. Despite significant advances in immunotherapy for IMG, fundamental questions persist, including optimal timing and combination strategies, mechanisms underpinning treatment resistance, and strategies to overcome the suppressive microenvironment. Future exploration of these treatment modalities, with a focus on mitigating soluble immunosuppressive factors in the TME, enhancing in situ T cell persistence, and leveraging novel antigen targets, is critical for advancing the state of therapy for this presently incurable group of tumors.


  • Open Access

    Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

    by Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang, Thomas James Flotte, Eric P Grewal, Robert R McWilliams, Lisa A Kottschade, Evidio Domingo-Musibay, et al.

    Background Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological response rates, while immunotherapy regimens show favorable recurrence-free survival (RFS). NeoACTIVATE was designed to address whether a neoadjuvant combination of both targeted therapy and immunotherapy might leverage the benefits of each. Methods We tested neoadjuvant treatment with 12 weeks of vemurafenib, cobimetinib, and atezolizumab for patients with BRAF-mutated (BRAFm) melanoma (cohort A) and cobimetinib and atezolizumab for patients with BRAF-wild-type (BRAFwt) melanoma (cohort B), regimens which we have shown generate a substantial major pathological response. After therapeutic lymph node dissection, patients received 24 weeks of adjuvant atezolizumab. Here, we report survival outcomes and their association with biomarkers assayed among the gut microbiome and peripheral blood immune subsets. Results With 49 months median follow-up, the median RFS was not reached for cohort A and was 40.8 months for cohort B. At 24 months after operation, 2 of 14 cohort A patients and 4 of 13 cohort B patients had experienced distant relapse. Key findings from correlative analyses included diversity, taxonomic and functional metagenomic gut microbiome signals associated with distant metastasis-free survival at 2 years. Notably, we observed a strong correlation between low microbial arginine biosynthesis (required for T-cell activation and effector function) and early distant recurrence (p=0.0005), which correlated with taxonomic differential abundance findings. Peripheral blood immune monitoring revealed increased double-positive (CD4+CD8+) T cells in patients with early recurrence. Conclusions Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib was associated with a low rate of distant metastasis in patients with high-risk stage III melanoma. Freedom from early distant metastasis was highly associated with taxonomic differences in gut microbiome structure and with functional pathway alterations known to modulate T cell immunity. Identification of predictive biomarkers will permit optimization of neoadjuvant therapy regimens for individual patients. Trial registration number NCT03554083.


  • Open Access

    Supplementary Figure S2 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma

    by Eric P. Grewal, Leland G.K. Richardson, Jing Sun, Rishab Ramapriyan, Maria Martinez-Lage, Julie J. Miller, Bob S. Carter, Daniel P. Cahill, William T. Curry, Bryan D. Choi

    Supplementary Figure 2. Quantitation of additional myeloid cell subtypes in murine IDH-wildtype and IDH-mutant glioma

  • Open Access

    Supplementary Table S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma

    by Eric P. Grewal, Leland G.K. Richardson, Jing Sun, Rishab Ramapriyan, Maria Martinez-Lage, Julie J. Miller, Bob S. Carter, Daniel P. Cahill, William T. Curry, Bryan D. Choi

    Supplementary Table 1. Clinical characteristics of glioma patients and samples

  • Open Access

    Supplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma

    by Eric P. Grewal, Leland G.K. Richardson, Jing Sun, Rishab Ramapriyan, Maria Martinez-Lage, Julie J. Miller, Bob S. Carter, Daniel P. Cahill, William T. Curry, Bryan D. Choi

    Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma

  • Open Access

    Supplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma

    by Eric P. Grewal, Leland G.K. Richardson, Jing Sun, Rishab Ramapriyan, Maria Martinez-Lage, Julie J. Miller, Bob S. Carter, Daniel P. Cahill, William T. Curry, Bryan D. Choi

    Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma